Epidemiological evidence strongly suggests an association between cigarette smoking and pancreatic diseases. It is well recognized that nicotine, a major component in cigarette smoke, is an addictive agent and, therefore, reinforces smoking behavior. The current review update focuses on the genetics of nicotine dependence and its role on the development of pancreatic diseases. The role of smoking and nicotine in pancreatitis and pancreatic cancer development is also discussed. Exposure of laboratory animals to nicotine clearly supports the notion that nicotine can induce pancreatic injury. The mechanism by which nicotine induces such effects is perhaps mediated via signal transduction pathways in the pancreatic acinar cell, leading to enhanced levels of intracellular calcium release, resulting in cytotoxicity and eventual cell death. The induction of pancreatic injury by nicotine may also involve activation and expression of protooncogene, H-ras, which can increase cytosolic calcium via second messenger pathways. Development of pancreatic carcinoma in cigarette smokers as observed in human populations may be the result of activation and mutation of the H-ras gene. A possible pathogenetic mechanism of nicotine in the pancreas activating multiple signal transduction pathways is schematically summarized in Figure 1.
ChowdhuryP, RayfordPL, ChangLW. Pathophysiological effects of nicotine On the pancreas. Proc Soc Exp Biol Med218:168–173, 1998.
2.
MillerNS. Nicotine addiction as a disease In: CocoresJA, Ed. The Clinical Management of Nicotine Dependence. New York: Springer-Verlag, pp66–78, 1991.
3.
Surgeon General.The Health Consequences of Using Smokeless Tobacco. USPHS, Bethesda, MD, NIH Publication #86-2874, 1986.
4.
U.S. Public Health Service: Smoking and health: A report of the Surgeon General, Department of Health, Education and Welfare, Public Health Service, Office of the Assistant Secretary for Health, Office of Smoking and Health (DHEW Publication No. PHS79-50066). Washington, D.C.: U.S. Government Printing Office, pp13–41, 1979.
5.
OkuyemiKS, HarrisJ, AhuwaliaJS, WallaceDD. Documentation of smoking: role of age, gender and ethnicity. J Assoc Minor Acad Physicians12:125–128, 2001.
CaudryM, BonnelC.Adenocarcinoma of the exocrine pancreas: management and therapeutic hopes. Rev Med Intern20:810–815, 1999.
8.
USDHHS. Smoking Cessation: Clinical Practice Guideline: Rockville, MD: Public Health Service, Agency for Health Care Policy and Research, 1996.
9.
RossG, ColwellL.Randomized controlled trial of smoking advice: final 20 year results. J Epidemiol Commun Health46:75–77, 1992.
10.
FernandezE, La VecchiaC, PortaM, NegriE, d'AvanzoB, BoyleP.Pancreatitis and the risk of pancreatic cancer. Pancreas11:185–189, 1995.
11.
WynderEL, MabuchiK, MaruchiN, FortnerJG. Epidemology of cancer of the Pancreas. J Natl Canc Inst50:645–667, 1973.
12.
GoldEB, CameronJL. Chronic pancreatitis and the risk of pancreatic cancer. N Engl J Med323:1485–1486, 1993.
13.
LowenfelsAB, MaisonneuveP, CavallineG, AmmannRW, LankischPG, AndersonJR, DiMagnoEP, Andren-SanbergA, DomillofA.The International Pancreatic Study Group. Pancreatitis and risk of pancreatic cancer. N Engl J Med328:1433–1437, 1993.
14.
MackTM, YuMc, HanischR, HendersonBE. Pancreas cancer and smoking, beverage consumption and past medical history. J Natl Cancer Inst76:49–60, 1986.
15.
FarrowDC, DavisS.Risk of pancreatic cancer in relation to medical history and use of tobacco, alcohol and coffee. Int J Cancer45:816–820, 1990.
16.
SilvermanDT, DunnJA, HooverRN, SchiffmanM, LillmoeKD, SchoenbergJB, BrownLM, GreenbergRS, HayesRB, SwansonGM, WacholderS, SwartzAG, LiffJM, PatternLM. Cigarette smoking and pancreas cancer: a case control study based on direct interviews. J Natl Cancer Inst86:1510–1516, 1986.
OlsenGW, MandelJS, GibsonRW, WattenburgLW, SchumanLM. A case control study of the pancreatic cancer and cigarettes, alcohol coffee and diet. Am J Public Health79:1016–1019, 1989.
19.
Bueono de MesquitaHB, MaisonneuveP, MoermanCJ, RuniaS, BoyleP.Life time history of smoking and exocrine carcinoma of the pancreas: population based case control study in the Netherlands. Int J Cancer49:846–822, 1991.
20.
ZatonskiWA, BoyleP, PrzewozniakK, MaisonneuveP, DrosikK, WalkerAM. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: a case control study from Opole, Poland. Int J Cancer53:601–607, 1993
21.
HoweGR, JainM, BurchJD, MillerAB. Cigarette smoking and cancer of the pancreas: evidence from a population based case control study in Toronto, Canada. Int J Cancer47:323–328, 1991.
22.
U.S. Dept Health and Human Services. The Health Benefits of Smoking Cessation: A Report of Surgeon General, 1990. DHHS Publication No. (CDC) 90-8416. Washington, D.C.: CDC PHS DHHS, 1990.
23.
RivensonA, HoffmanD, ProkopczykB, AminS, HechtSS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco specific any areca derived N-nitrosamines. Cancer Res48:6912–6917, 1988.
24.
PourPM, RivensonA.Induction of a mixed ductal-squamous-islet cell carcinoma in a rat treated with a tobacco-specific carcinogen. Am J Pathol134:627–631, 1989.
25.
ChowdhuryP, RayfordPL, ChangLW. Inductions of pancreatic acinar cell pathology via inhalation of nicotine. Proc Soc Exp Biol Med20:159–164, 1992.
26.
ChowdhuryP, HosotaniR, ChangLW, RayfordPL. Metabolic and pathologic effects of nicotine on the gastrointestinal tract and pancreas of rats. Pancreas5:222–229, 1990.
27.
ChowdhuryP, AmiM, HosotaniR, RayfordPL. Meal stimulated exocrine pancreatic secretion and release of GI peptides in normal and nicotine treated rats. Regul Peptides33:11–20, 1991.
28.
DubickMA, PalmerR, LauPP, MorrillRR, GeokasMC. Altered exocrine pancreatic function in rats treated with nicotine. Toxicol Appl Pharmacol96:132–139, 1988.
29.
MajumderAPN, DavisGA, DubickMA, GeokasMC. Nicotine stimulation of protein secretion from isolated rat pancreatic acini. Am J Physiol248:G158–G163, 1985.
30.
LauPP, DubickMA, YuGS, MorillPR, GeokasMC. Dynamic changes of pancreatic structure and function of rats treated chronically with nicotine. Toxicol Appl Pharmacol104:457–465, 1990.
31.
ChowdhuryP, DoiR, TangokuA, RayfordPL. Structure and functional changes of rat exocrine pancreas exposed to nicotine. Int J Pancreatol18:257–264, 1995.
32.
ChengLS, SwanGE, CarmelliDA. Genetic analysis of smoking behavior in family members of older adult males. Addiction95:427–435, 2000.
33.
CarmelliD, SwanGE, RobinettD, FabsitzR.Genetic influence on smoking—a study of male twins [see comments]. N Engl J Med327:829–833, 1992.
34.
SwanGE, CarmelliD, CardonLR. The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. J Substance Abuse8:19–31, 1996.
35.
NobleEP, St. JeorST, HughesGR. Genetics of smoking: a brief review. Behavior Ther17:335–345, 1986.
36.
NobleEP, RitchieT, SyndulkoK, St. JeorST, FitchRJ, BrunnerRL, SparkesRS. D2 dopamine receptor gene and cigarette smoking: a reward gene? Medical Hypotheses42:257–260, 1994.
37.
NobleEP. The DRD2 gene, smoking, and lung cancer [editorial; comment]. J Natl Cancer Inst90:343–345, 1998.
OscarsonM, Gullsten, RautioA, BernalML, SinuesB, DahlML, StengardJH, PelkonenO, RaunioH, Ingelman-SundbergM.Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine Coxidase. FEBS Lett438:201–205, 1998.
40.
OscarsonM, McLellanRA, GullstenH, AgundezJ A, BenitezJ, RautioA, RaunioH, PelkonenO, Ingelman-SundbergM.Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett460:321–327, 1999.
41.
OscarsonM, McLellanRA, GullstenH, YueQY, LangMA, BernalML, SinuesB, HirvonenA, RaunioH, PelkonenO, Ingelman-SundbergM.Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett448:105–110, 1999.
42.
ZabetianCP, GelernterJ, CubellsJF. Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence. Am J Medical Genet96:638–645, 2000.
43.
AyeshR, IdleJR, RitchieJC, CrothersMJ, HetzelMR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature312:169–170, 1984.
44.
ChristensenPM, GotzschePC, BrosenK.The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol51:389–393, 1997.
45.
Legrand-AndreolettiM, StuckerI, MarezD, GalaisP, CosmeJ, SabbaghN, SpireC, CeneeS, LafitteJJ, BeauneP, BrolyF.Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics8:7–14, 1998.
46.
WiseRA, RomprePP. Brain dopamine and reward. Ann Rev Psychol40:191–225, 1989.
47.
KoobGF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci13:177–184, 1992.
48.
BrazellMP, MitchellSN, JosephMH, GrayJA. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology29:1177–1185, 1990.
49.
PontieriFE, TandaG, OrziF, Di ChiaraG.Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs [see comments]. Nature382:255–257, 1996.
50.
PontieriFE, PassarelliF, CaloL, CarontiB.Functional correlates of nicotine administration: similarity with drugs of abuse. J Mol Med76:193–201, 1998.
51.
NobleEP, BlumK, RitchieT, MontgomeryA, SheridanPJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archi Gen Psych48:648–654, 1991.
52.
PohjalainenT, RinnieJO, NagrenK, LehikoinenP, AnttilaK, SyvalahtiEK, HietalaJ.The Al allele if the human D2 receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psych3:256–260, 1998.
53.
SpitzMR, ShiH, YangF, HudmonK S, JiangH, ChamberlainRM, AmosCI, WanY, CinciripiniP, HongWK, WuX.Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients [see comments]. J Natl Cancer Inst90:358–363, 1998.
54.
ComingsDE, FerryL, Bradshaw-RobinsonS, BurchetteR, ChiuC, MuhlemanD.The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics6:73–79, 1996.
55.
LeschKP, BengelD, HeilsA, SabolSZ, GreenbergBD, PetriS, BenjaminJ, MullerCR, HamerDH, MurphyDL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region [see comments]. Science274:1527–1531, 1996.
56.
HuS, BrodyCL, FisherC, GunzerathL, NelsonML, SabolSZ, SirotaLA, MarcusSE, GreenbergBD, MurphyDL, HamerDH. Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Mol Psych5:181–188, 2000.
57.
LermanC, CaporasoNE, AudrainJ, MainD, BoydNR, ShieldsPG. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psych5:189–192, 2000.
58.
BrockmanD.Development of the pancreas. In: BergerHG, WarshawAL, BuchlerMW, Car-LockeDLNeoptolemosJP, RussellC, SarrMG, Eds. The Pancreas. Oxford, UK:Blackwell Science Vol 1:pp3–10, 1988.
59.
NauckMA. Physiology and pathophysiology of endocrine pancreatic secretion. In: BergerHG, WarshawAL, BuchlerMW, Car-LockeDL, NeoptolemosJP, RussellC, SarrMG, Eds. The Pancreas. Oxford, UK: Blackwell Science Publishers, Vol 1:pp101–137, 1988.
60.
Tobacco Research Implementation Group, National Cancer Institute, National Institutes of Health. Tobacco Research Implementation Plan, Priorities for Tobacco Research Beyond the Year 2000, November [Monograph]. Bethesda, MD, 1998.
61.
WeiderpassE, PartanenT, KaaksR, VaunioH, PortaM, KauppinenY, OjajarviA, BofettaP, MalatsN.Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health24:165–174, 1998.
62.
GoldEB, GoldinSB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin North Am7:67–91, 1998.
63.
NiderhuberJE, BrennonMF, MenckHR. The National Cancer Data Base Report on Pancreatic Cancer. Communication from the American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer76:1671–1677, 1995.
64.
HirayamaT.Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol19:208–215, 1989.
65.
ShibataA, MackTM, Paganini-HillA, RossRK, HendersonBE. A prospective study of pancreatic cancer in the elderly. Int J Cancer58:46–49, 1994.
66.
CavalliniG, TalaminiG, VaonaB, BovoP, FillippiniM, RigoL, AngeliniG, VantiniI, RielaA, FrulloniL.Effect of alcohol and smoking on pancreatic lithogenesis in the course of chronic pancreatitis. Pancreas9:42–46, 1994.
67.
TalaminiG, BassiC, FalconiM, FrulloniL, Di FrancescoB, VaonaB, BovoP, RigoL, CastaginiA, AngeliniG, VantiniI, PederzoliP, CavalliniG.Cigarette smoking: an independent risk factor in alcoholic pancreatitis. Pancreas12:131–137, 1996.
68.
LowenfelsAB, MaisonneuveP, CavalliniG, AmmannRW, LankischPG, AndersonJR, DimagnoEP, Andren-SandbergA, DomellofL.Pancreatitis and the risk of pancreatic cancer. International Pancreatic Study Group. N Engl J Med328:1433–1437, 1993.
69.
KarlsonBM, EkbomA, JosefssonS, McLaughlinJK, FraumeniJF, NyrenO.The risk of pancreatic cancer following pancreatitis: an association due to confounding?Gastroenterology113:587–592, 1997.
70.
PourPM, TakahashiM, DonnellyT, StepanK.Modification of pancreatic carcinogenesis in hamster model. IX. Effect of pancreatitis. J Natl Cancer Inst71:607–613, 1983.
71.
SandgreenEP. Mouse models of exocrine pancreatic cancer. In: Pancreatic Cancer: From Genes to Treatment. Baltimore, MD: John Hopkins University School of Medicine Conference Proceedings (June 2001 Scientific Meeting of the Lustgarten Foundation for Pancreatic Cancer Research), June 14, p20, 2001.
72.
CashmanJR, ParkSB, YangZC, WrightonSA, JacobPIII, BenowitzN.Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N&p-oxide. Chem Res Toxicol5:639–646, 1992.
73.
HoffmannD, HechtSS. Nicotine derived N-nitrosoamines and tobacco related cancer: current status and future directions. Cancer Res45:935–944, 1985.
74.
HechtSS, HoffmannD.Tobacco specific nitrosoamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis9:875–884, 1988.
75.
CannellaSG, KaganSS, HechtSS. Evidence that a hemoglobin adduct of 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone is a 4-(3-pyridyl)-4-oxibutyl carboxylic acid ester. Chem Res Toxicol5:76–80, 1992.
76.
ShigenegaMK, TrevorAJ, CastangoliNJr.Metabolism-dependent covalent binding of (S)-(5-3H) nicotine to liver and lung microsomal macromolecules. Drug Metab Disposition16:397–402, 1988.
77.
BelinskySA, WhiteCM, BaucheronJA, RichardsonFC, SwenbergJA, AndersonM.Accumulation and persistence of DNA adducts in respiratory tissue of rat following multiple administration of the tobacco-specific carcinogen 4-(N-methyl-N-nitrosoamino)-1-(3-pyridyl)-1-butanone. Cancer Res46:1280–1284, 1986.
78.
HammondDK, BjerckeRJ, LangoneJJ, StrobelHW. Metabolism of nicotine by rat liver cytochromes P-450: assessment utilizing monoclonal antibodies to nicotine and cotinine. Drug Metabolism Disposition19:804–808, 1991.
79.
NakayamaH, OkudaH, NakashimaT, ImaokaS, FunaeY.Nicotine metabolism by rat hepatic cytochrome P450 S. Biochem Pharmacol45:2554–2556, 1993.
80.
OscarsonM, GullstenH, RautioA, BernalML, SinuesB, DahlML, StengardJH, PelkonenO, RaunioH, Ingelman-SundbergM.Genotyping of human cytochrome P 450 2A6 (CYP2A6), a nicotine Coxidase. FEBS Lett438:201–205, 1998.
81.
HaniokaN, JinnoH, KitazawaK, Tanaka-KagawaT, NishimuraT, AndoM, OgawaK.In vitro biotransformation of atrazine by rat liver microsomal cytochrome p 450 enzymes. Chem Biol Interact116:181–198, 1998.
82.
LombardiB, EstesLW, LongneckerDS. Acute hemorrhagic pancreatitis c massive necrosis) with fat necrosis induced in mice by DL-ethionine with a choline-deficient diet. Am J Pathol79:464–480, 1975.
83.
NiederauC, FerrellLD, GrendellJH. Caerulein induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript and secretin. Gastroenterology88:1192–1204, 1985.
84.
WatanabeI, BaccinoFM, SteerML, MeldolesiJ.Supromaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cells early morphological alterations during development of experimental pancreatitis. Am J Physiol246:G457–G467, 1984.
85.
KoikeK, SteerML, MeldolesiJ.Pancreatic effects of ethionine, blockade of exocytosis, and appearance of crinophagy and autophagy preceding cellular necrosis. Am J Physiol242:G297–G307, 1982.
86.
AdlerG, HahnC, KernHF, RaoKN. Caerulein induced pancreatitis in rats: increased lysosomal enzyme activity and autophagocytosis. Digestion32:10–18, 1985.
87.
NiederauC, GrendallJH. Intracellular vacuoles in experimental acute pancreatitis in rats and mice are an acidified compartment. J Clin Invest81:229–236, 1988.
88.
RaoK, ZurettiN, RaccinoM, LombardiB.Acute hemorrhaegic pancreatitis in mice. The activity of lysosomal enzymes in the pancreas and liver. Am J Pathol98:45–59, 1980.
89.
NiederauC, VanDykeRW, ScharschmidtBF, GrendellJH. Rat pancreatic zymogen granules: an actively acidified compartment. Gastroenterology91:1433–1442, 1986.
90.
SteerML, MeldolesiJ, FigarellaC.Pancreatitis: the role of lysosomes. Dig Dis Sci29:934–938, 1984.
91.
YamaguchiH, KimuraT, MimuraK, NawataH.Activation of proteases in caerulein-induced pancreatitis. Pancreas4:565–571, 1989.
92.
KalapothakiV, TzonouA, HsiehCC, ToupadakiN, KarakatsaniA, TrichopoulosD.Tobacco, ethanol, coffee, pancreatits, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control4:375–382, 1993.
93.
HedbergM, JanzonL, RehfeldJF, BorgstromA.Long-term effects on the regulation of pancreatic secretion after gastric surgery. Dig Surg16:111–116, 1999.
94.
al-EryaniS, DurisI, PayerJ, HuorkaM, KratochvilovaH, OndrejkaP.Plasma cholecystokinin and somatostatin levels in chronic pancreatitis patients. Hepatogastroenterology33:869–874, 2000.
95.
ChowdhuryP, DoiR, TangokuA, and RayfordPL. Structural and functional changes of rat pancreas exposed to nicotine. Int J Pancreatol18:257–264, 1995.
96.
ChowdhuryP, RayfordPL. Effect of food restriction on plasma cholecystokinin levels and exocrine pancreatic function in rats. Ann of Clin Lab Sci31:376–382, 2001
97.
WinterTA, MarksT, CallananM, O'KeefeSJ, BridgerS.Impaired pancreatic secretion in severly malnourished patients is a consequence of primary pancreatic dysfunction. Nutrition17:230–235, 2000.
98.
BrownP.The influence of smoking on pancreatic function in man. Med J Aust2:290–293, 1976.
99.
MurthySNS, DinosoVPJr., ClearfieldHR, CheyWY. Simultaneous measurements of basal, pancreatic, gastric acid secretion, plasma gastrin and secretin during smoking. Gastroenterology73:758–761, 1977.
100.
KonturekSJ, SolomonTE, McGreightWG, JohnsonLR, JacobsonWD. Effect of nicotine on gastrointestinal secretions. Gastroenterology13:361–365, 1972.
101.
BynumTE, SolomonTE, JohnsonLR. Jacobson ED. Inhibition of pancreatic secretion in man by cigarette smoking. Gut13:361–365, 1972.
102.
SolomonTE, SolomonN, ShanbourLL, JacobsonED. Direct and indirect effects of nicotine on rabbit pancreatic secretion. Gastroenterology67:276–283, 1974.
103.
HeikiusB, NeimelaS, LehtolaJ, KarttunenTJ. Elevated pancreatic enzymes in inflammatory bowl disease are associated with extensive disease. Am J Gastroenterol94:1062–1069, 1999.
104.
ChowdhuryP, BoneRC, LouriaDB, RayfordPL. Effect of cigarette smoke on human trypsin inhibitory capacity and antitrypsin concentrationsAm Rev Resp Dis126:177–179, 1982.
105.
RichterJM, MayRJ. Disorders of the pancreas. In: ChopraS, MayRJ, eds. Pathology of the Gastrointestinal Diseases. Boston: Little Brown & Co, pp529–573, 1990.
106.
BloomSR. Clinical Syndromes of gut hormones. In: Thompson JC, ed. Gastrointestinal Endocrinology, Receptors, and Postreceptor Mechanisms. New York: Academic Press, pp479–490, 1990.
107.
KontuerekSJ. Gastrointestinal hormones and gastric secretion. In: Jerzy GB, ed. Gastrointestinal Hormones. New York: Raven Press, pp529–564, 1990.
108.
CheyWY. Gastrointestinal Hormones, pancreatic biliary and intestinal secretins. In: In: Jerzy GB, ed. Gastrointestinal Hormones. New York: Raven Press, pp565–586, 1980.
109.
WilliamsJA, KorcM, DormerRL. Action of secretagogues on a new preparation of functionally intact isolated pancreatic acini. Am J Physiol235:E517–E524, 1978.
110.
SchmidtJ.LewandrowskikFernandez-del Castillo, MandaielliU, ComptonCEWarshawAL, RattnerDW. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis Dig Dis Sci37:1426–1433, 1992.
111.
AgarwalN.Pitchumoni, Sivaprasad AV. Evaluating tests for acute pancreatitis. Am J Gastroenterol85:356–366, 1990.
112.
NordestgaardAG, WilsonSE, WilliamsRA. Correlation of serum amylase levels with pancreatic pathology and pancreatitis etiology. Pancreas3:159–161, 1988.
113.
DubickMA, MarG, MayerAD, MaJumderAPN, McMahonMJ, GeokasMC. Digestive enzymes and protease inhibitors in plasma from patients with acute pancreatitis. Pancreas2:187–194, 1987.
114.
AndriulliA, MasoeroG, AmatoA, FelderM, BenittiV, DobrillaG, De la PierreM, VermeG.Serum immunoreactive cationic trypsinogen response to secretin in normal subjects. Am J Gastroentrol78:579–583, 1983.
115.
WilliamsJA, HootmanSR. Stimulus-secretion coupling in pancreatic acinar cells. In: Gro VLW, BrooksFB, DimagnoEP, etal., Eds. Exocrine Pancreas: Biology, Pathology and Diseases. New York: Raven Press, pp123–139, 1986.
116.
BestermanHS, AdrianTE, BloomSR, ChristofidesND, MallinsonCN, PontiV, LombardoL, ModiglianiRGuerinS, SouthM.Pancreatic and gastrointestinal hormones in chronic pancreatitis. Digestion24:195–208, 1982.
117.
BruzzoneR.The molecular basis of enzyme secretion. Gastroenterology99:1157–1176, 1990.
118.
DoiR, ChowdhuryP, RayfordPL. Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem268:22436–22443, 1993.
119.
BrannonPM. Primary cultures of pancreatic acinar cells. In: Thompson JC, Ed. Gastrointestinal Endocrinology Receptors and Post-Receptor Mechanisms. New York: Academic Press, Vol 16:pp199–209, 1990.
120.
BrannonPM, OrissonDM, KretchmerN.Primary cultures of rat pancreatic acinar cells in serum free medium. In Vitro Cell Dev Biol21:6–14, 1985.
121.
NeerEJ. Heterotrimeric G Proteins: organizer of transmembrane signals. Cell80:249–257, 1995.
122.
ChowdhuryP, DoiR, NishikawaM, TakaoriK, RayfordPL. Carbachol and cholecystokinin enhance accumulation of nicotine in rat pancreatic acinar cells. Pancreas10:154–160, 1995.
123.
HillardCJ. Neurochemistry of nicotine. In: Watson RR, Ed. Drugs of Abuse and Neurobiology. Boca Raton, FL: CRC Press, pp85–114, 1992.
124.
WonnacottS.The paradox of nicotine acetylcholine receptor up regulation by nicotine. Trends Pharmacol Sci11:216–219, 1990.
125.
SchwartzRD, KellerKJ. In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem45:427–433, 1985.
126.
SchwartzRD, KellerKJ. Nicotine cholinergic receptor binding sites in the brain: regulation in vivo. Science220:214–216, 1983.
127.
MarksMJ, BurchJB, CollinsAC. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther226:817–825, 1983.
128.
MarksMJ, StitzelJA, CollinsA.Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther235:619–628, 1985.
129.
BenwellME, BelfourDJK, AndersonJM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem50:1243–1247, 1988.
130.
MilediR, ParkerI, SchalowG.Transmitter induced calcium entry across post synaptic membrane of frog end plates measured using arsenazo III. J Physiol300:197–212, 1980.
131.
WadaA, TadaraH, IzumiF, KobayashiH, YaniharaN.Influx of 22Na through acetylcholine receptor associated Na channels: relationship between 22Na influx, 45Ca influx and secretion of catecholamines in cultured bovine adrenal medulla cells. Neuroscience15:283–292, 1985.
132.
CenaV, NicholasGP, Sanchez-GarciaP, KirpekarSM, GarciaAG. Pharmacological dissection of receptor associated and voltage sensitive ionic channels involved in catecholamine release. Neuroscience10:1455–1462, 1983.
133.
BoarderM, MarriottD, AdamsM.Stimulus secretion coupling in cultured chromaffin cell dependency on external sodium and on dihydropyridine sensitive calcium channels. Biochem Pharmacol36:163–167, 1987.
134.
HillardCJ. Effects of nicotine and nicotine agonist on calcium influx into brain synaptosomes. NIDA Mongraph Serv81:324, 1988.
135.
BurgoyneRD. The relationship between secretion and intracellular free calcium in bovine adrenal chromaffin cells. Biosci Rep4:605–611, 1984.
136.
EberhardDA, HolzRW. Cholinergic stimulation on inositol monophosphate formation in bovine adrenal chromaffin cells: distinct nicotinic and muscarninic mechanisms. J Neurochem49:1634–1643, 1987.
137.
FirestoneJA, BrowningMD. Calcium signalling in bovine adrenal chromaffin cells: additive effects of histamine and nicotine. Synapse17:268–274, 1994.
138.
NakakiT, SasakawaN, YamamotoS, KatoR.Functional shift for muscarinic to nicotinic cholinergic receptors involved in inositol triphosphate and cyclic GMP accumulation during primary culture of adrenal chromaffin cells. Biochem J251:397–403, 1988.
139.
SasakawaN, NakakiT, KatoR.Rapid increase in inositol penkisphosphate accumulation by nicotine in cultured adrenal chromaffin cells. FEBS Lett261:378–380, 1990.
140.
TerBushDR, BittnerMA, HoltRW. Ca2+ influx causes rapid translocation of protein kinase C to membranes. J Biol Chem262:18873–18879, 1988.
141.
TravaliS, KonieckiJ, PetraliaS, BasergaR.Oncogenes in growth and development. FASEB J4:3209–3214, 1990.
142.
ZhangGH, MelvinJE. Nicotine increases [Ca2+]i in rat sublingual mucous acini by stimulating neurotransmitter release from presynaptic terminals. Proc Soc Exp Biol Med207:292–301, 1994.
143.
HillardCJ, GrafWK. Studies of the effect of nicotine on synaptosomal calcium accumulation using Fura-2. NIDA Res Monograph165:331–332, 1990.
144.
HunterT.Cooperation between oncogenes. Cell64:249–270, 1991.
145.
CowleyB, ChadwickL, GranthamJ, CalvertJ.Sequential protooncogene expression in regenerating kidney following acute renal injury. J Biol Chem264:8389–8393, 1989.
146.
IovannaJL, Lechene de La PorteP, DagornJC. Expression of genes associated with dedifferentiation and cell proliferation during pancreatic regeneration following acute pancreatitis. Pancreas7:712–718, 1992.
147.
IovannaJL, KeimV, MichelR, DagornJC. Pancreatic gene expression is altered during acute experimental pancreatitis in the rat. Am J Phyisol261:485–489, 1991.
148.
SlamanD, ClineM.Expression of cellular oncogenes during embryonic and fetal development of the mouse. Proc Natl Acad Sci U S A81:7141–7145, 1984.
149.
ZimmermanK, YancopoulosG, CollumR, SmithRK, KohlNE, DenisKA, NanMM, WitteON, Toran-AllerandD, GeeCE, MinnaJD, AltFW. Differential expression of myc family genes during marine development. Nature319:780–783, 1986.
150.
MullerR, SlamonD, TremblayJ, ClineM, VermaI.Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature299:640–644, 1982.
151.
CalvoE, DussettiN, CadenasMB, DagornJC, IovannaJL. Changes in gene expression during pancreatic regeneration: activation of cmyc and H-ras oncogenes in the rat pancreas. Pancreas6:150–156, 1991.
152.
ChowdhuryP, MontagueDC, RayfordPL, ChangLW, Lyn-CookB-D. Nicotine alters pancreatic gene (Ha-ras) expression and induces point mutation and exocrine pancreatic injury. XVI Proceedings of the International Cancer Congress. New Delhi, India. Rao RS, DeoMG, SanghviLD, MitraI, eds. Bologna, Italy: Monduzzi Editoire, pp369–373, 1994.
153.
AlonsoT, SrivastavaS, SantosE.Alterations of G-protein coupling function in phosphoinositide signaling pathways of cells transformed by ras and other membrane-associated and cytoplasmic oncogenes. Mol Cell Biol10:3117–3124, 1990.
154.
GibbsJB, MarshallMS, ScolnickEM, DixonRAF, VogelUS. Modulation of guanine nucleotides bound to ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP). J Biol Chem265(33):20437–20442, 1990.
155.
ValenciaA, KjeldgaardM, PaiEF, SanderC.GTPase domains of ras p21 oncgene protein and elongation factor Tu: analysis of three-dimensional structures, sequence families, and functional sites. Proc Natl Acad Sci U S A88:5443–5447, 1991.
156.
SchanneFA, KaneAB, YoungEE, FarberJL. Calcium dependence of toxic cell death: a final common pathway. Science206:700–702, 1979.
MajumdarAPN, VesenkaGD, DubickMA, GeokasMC. Evaluation of the role of calcium in cytotoxic injury in isolated rat pancreatic acini. Biochem Biophys Res Commun139:530–537, 1986.
159.
HaubruckH, McCormickF.Ras p21: effects and regulation. Biochem Biophys Acta1072:215–229, 1991.
160.
MarxJ.Two major signal pathways linked. Science262:988–990, 1993.
161.
MulachyLS, SmithMR, StaceyDW. Requirements for ras protooncogene function during serum-stimulated growth of NIH 3T3 cells. Nature313:241–243, 1985.
162.
BeitelGJ, ClarkSG, HorvitzHR. Caehorhabditis elegans ras gen let-60 acts as a switch in the pathway of vulval induction. Nature348:503–509, 1990.
163.
SimonMA, BowtellDD, DodsonGS, LavertyTR, RubinGM. Ras 1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell67:701–716, 1991.
164.
BourneHR, SandersDA, McCormickF.The GTPase superfamily: a conserved switch for diverse cell functions. Nature348:125–132, 1990.
165.
CapellaG, Cronauer-MitraS, PeinadoMA, PeruchoM.Frequency and spectrum of mutations at condons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Persp93:125–131, 1991.
166.
BarbacidM.Ras gene. Annu Rev Biochem56:779–827, 1987.
167.
MarxJ.Forging a path to the nucleus. Science260:1588–1590, 1993.
